Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor

► Biomarker signatures were developed to predict histological treatment response to lanifibranor treatment in patients with MASH and fibrosis